Rezolute (RZLT) Price & Analysis

Compare

592 Followers

RZLT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.22 - $6.65

Previous CloseN/A

Volume107.87K

Average Volume (3M)1.36M

Market Cap

$517.63M

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Sep 11, 2025

EPS Estimate

-0.22

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding86,995,990

10 Day Avg. Volume1,181,801

30 Day Avg. Volume1,363,314

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$13.60

Price Target Upside128.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical TrialsThe ongoing Ph3 sunRIZE study of ersodetug in congenital hyperinsulinism will continue as planned with no need to increase sample size based on the DMC's recommendation following a pre-specified interim analysis.

Efficacy And SafetyApproval for infant patient enrollment confirms ersodetug's safety, which is important as the age range represents the most dynamic phase of the disease.

Regulatory ApprovalRZLT has reached an alignment with the FDA on moving directly into a Ph3 registrational study based on positive data from an active expanded access program.

Bears Say

Placebo EffectThe Ph3 study was designed to show a 35% improvement from placebo in hypoglycemia control, assuming the highest possible placebo effect to be 35%.

Rezolute News

Rezolute files to sell 1.3M shares of common stock for holders

17:02 EDT Rezolute (RZLT) files to sell 1.3M shares of common stock for holders Published first on TheFly...

16d ago

RZLT

Rezolute Completes Enrollment for Phase 3 sunRIZE Study

The latest update is out from Rezolute ( ($RZLT) ). On July 15, 2025, Rezolute, Inc. announced the...

15d ago

RZLT

Promising Future for Rezolute’s Ersodetug in Treating Congenital Hyperinsulinism: Analyst Recommends Buy

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Rezolute, with a price...

17d ago

RZLT

Positive Buy Rating for Rezolute Driven by Promising Phase 3 Study Results and Strong Efficacy Potential

Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Rezolute. The associated price target remains the...

18d ago

RZLT

Rezolute Completes Private Stock Placement for $4.2M

An announcement from Rezolute ( ($RZLT) ) is now available. Rezolute announced that on June 13, 2025, it...

2M ago

RZLT

Rezolute’s Promising Outlook: Buy Rating Backed by Strong Clinical Progress and Financial Position

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Rezolute (RZLT – Research Report) and keeping...

2M ago

RZLT

Rezolute complete enrollment in Phase 3 sunRIZE study of ersodetug

Rezolute (RZLT) announced that enrollment is complete in the sunRIZE study, a global, Phase 3 multicenter, double-blind, randomized,...

2M ago

RZLT

Rezolute, Inc. (RZLT) Q3 Earnings Cheat Sheet

Rezolute, Inc. (RZLT) is scheduled to report 3rd quarter earnings on 05/20/2025, after the market closes. Regarding Q3...

3M ago

RZLT

Rezolute’s Financial Stability and Clinical Progress Drive Buy Rating Amid Promising Phase 3 Trials

Maxim Group analyst Jason McCarthy maintained a Buy rating on Rezolute (RZLT – Research Report) yesterday and set...

3M ago

RZLT

Rezolute’s Promising Market Position and Clinical Advancements Drive Buy Rating

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Rezolute (RZLT –...

3M ago

RZLT

Rezolute’s Ersodetug Shows Promise in Phase 3 Trials for CHI, Reinforcing Buy Rating and $12 Price Target

JonesTrading analyst Catherine Novack has reiterated their bullish stance on RZLT stock, giving a Buy rating yesterday. Catherine...

3M ago

RZLT

Optimistic Buy Rating for Rezolute Driven by Promising Ersodetug Developments and Strong Financial Position

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price...

3M ago

RZLT

Rezolute reports Q3 EPS (27c), consensus (24c)

“The Phase 3 sunRIZE study in congenital HI is on track to complete enrollment this month and we...

3M ago

RZLT

Rezolute announces FDA granted BTD to ersodetug

Rezolute (RZLT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to...

3M ago

RZLT

RZLT FAQ

What was Rezolute’s price range in the past 12 months?

Rezolute lowest stock price was $2.21 and its highest was $6.64 in the past 12 months.

What is Rezolute’s market cap?

Rezolute’s market cap is $517.63M.

When is Rezolute’s upcoming earnings report date?

Rezolute’s upcoming earnings report date is Sep 11, 2025 which is in 40 days.

How were Rezolute’s earnings last quarter?

Rezolute released its earnings results on May 20, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.229 by -$0.041.

Is Rezolute overvalued?

According to Wall Street analysts Rezolute’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Rezolute pay dividends?

Rezolute does not currently pay dividends.

What is Rezolute’s EPS estimate?

Rezolute’s EPS estimate is -0.22.

How many shares outstanding does Rezolute have?

Rezolute has 86,995,990 shares outstanding.

What happened to Rezolute’s price movement after its last earnings report?

Rezolute reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.229. Following the earnings report the stock price went up 1.519%.

Which hedge fund is a major shareholder of Rezolute?

Currently, no hedge funds are holding shares in RZLT

Rezolute Stock Smart Score

Outperform

Fundamentals

Return on Equity

-95.15%

Trailing 12-Months

Asset Growth

7.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Rezolute

Rezolute, Inc. (RZLT) is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and orphan diseases. The company is primarily engaged in the research and development of innovative treatments targeting serious conditions such as rare metabolic disorders. Its core product candidates include RZ358, an antibody designed to treat congenital hyperinsulinism, and RZ402, an oral therapy aimed at diabetic macular edema.

Rezolute (RZLT) Earnings & Revenues

RZLT Earnings Data >

RZLT Stock 12 Month Forecast

Average Price Target

$13.60

▲(128.57%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","16":"$16","4.75":"$4.75","8.5":"$8.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$15.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,4.75,8.5,12.25,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,5.233846153846153,6.047692307692308,6.861538461538462,7.6753846153846155,8.489230769230769,9.303076923076922,10.116923076923078,10.930769230769231,11.744615384615384,12.558461538461538,13.372307692307693,14.186153846153847,{"y":15,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,5.126153846153846,5.832307692307692,6.538461538461538,7.2446153846153845,7.950769230769231,8.656923076923077,9.363076923076923,10.069230769230769,10.775384615384615,11.481538461538461,12.187692307692307,12.893846153846154,{"y":13.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.42,5.003076923076923,5.586153846153846,6.169230769230769,6.752307692307692,7.335384615384616,7.918461538461538,8.50153846153846,9.084615384615384,9.667692307692308,10.25076923076923,10.833846153846153,11.416923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.76,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.31,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.41,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.76,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.9,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.25,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.42,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >